Detalles de la búsqueda
1.
HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.
Br J Cancer
; 115(6): 725-30, 2016 09 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27537387
2.
HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.
Br J Cancer
; 115(9): e15, 2016 10 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27711084
3.
Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system.
Acta Obstet Gynecol Scand
; 89(11): 1438-46, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20955098
4.
Data on RT-qPCR assay of nuclear progesterone receptors (nPR), membrane progesterone receptors (mPR) and progesterone receptor membrane components (PGRMC) from human uterine endometrial tissue and cancer cells of the Uterine Cervix.
Data Brief
; 31: 105923, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32671144
5.
Expression of nuclear progesterone receptors (nPRs), membrane progesterone receptors (mPRs) and progesterone receptor membrane components (PGRMCs) in the human endometrium after 6 months levonorgestrel low dose intrauterine therapy.
J Steroid Biochem Mol Biol
; 202: 105701, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32479983
6.
Early effects of high concentrations of progesterone and mifepristone A gene expression study of endometrial cancer cells (Ishikawa).
J Steroid Biochem Mol Biol
; 113(1-2): 139-49, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19138738
7.
High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis.
Anticancer Res
; 29(4): 1053-8, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19414345
8.
Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy.
Anticancer Res
; 29(4): 1047-52, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19414344
9.
Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction.
Acta Obstet Gynecol Scand
; 88(11): 1234-42, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19900140
10.
Intrauterine Progestin Therapy as a New Approach to Premalignant Endometrial Polyps: A Prospective Observational Study.
Anticancer Res
; 39(9): 4897-4903, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31519593
11.
Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
Gynecol Oncol
; 111(1): 68-73, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18684496
12.
Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone.
Steroids
; 73(1): 116-28, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18037150
13.
Regression of latent endometrial precancers by progestin infiltrated intrauterine device.
Cancer Res
; 66(11): 5613-7, 2006 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16740697
14.
Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.
Anticancer Res
; 38(5): 2883-2889, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29715112
15.
Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
Anticancer Res
; 27(4C): 2591-6, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17695420
16.
Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
Anticancer Res
; 37(5): 2529-2536, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28476823
17.
Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
Anticancer Res
; 35(12): 6401-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26637849
18.
Non-genomic effects of progestins--inhibition of cell growth and increased intracellular levels of cyclic nucleotides.
J Steroid Biochem Mol Biol
; 84(1): 1-8, 2003 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-12648518
19.
Non-genomic cell growth inhibition by progesterone. cell cycle retardation and induction of cell death.
Anticancer Res
; 24(6): 3749-55, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15736407
20.
Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.
Anticancer Res
; 34(5): 2319-24, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24778038